DE — Deere & Company

Sentiment is clearly bullish as of 2026-09-13. The stock returned -2.57% in the last week but +9.03% over one month, +17.02% over three months and +17.01% over six months, closing at $675.74 against a 52-week range of $433.00-$705.88. The drivers are concrete: a Q3 FY2026 EPS beat ($5.10 vs ~$4.69-4.72 consensus), a raised FY2026 net income outlook, management's 'cycle bottom' call, used high-horsepower tractor inventories down ~40% YoY signaling channel destocking is finished, and a Construction & Forestry segment where sales rose 18% and operating profit rose 84%. Baird upgraded to Outperform with an $800 target, and the 11-analyst consensus price target sits at $731.20. The crack in the story: consensus next-FY EPS is $18.13, essentially flat versus $18.06 TTM, so the bulls are paying up for a recovery that has not yet appeared in the estimate revisions themselves.

The three-year arc is a clean boom-bust-inflection shape, not a structural decline. Revenue fell hard through FY2025 (Q1 FY25 $8.26B, -30.2% YoY; Q2 FY25 $12.53B, -16.5%; Q3 FY25 $11.78B, -8.3%), then turned positive in FY2026 (Q1 $9.61B, +16.3%; Q2 $13.37B, +6.7%; Q3 $12.61B, +7.0%). Margins are improving but not uniformly: operating margin was 16.2% in Q1 FY26 (vs 17.9% YoY), 22.5% in Q2 (vs 23.0%), and 20.6% in Q3 (vs 18.3%, a ~230bp YoY expansion). Net income in the most recent quarter was $1.379B (+7.0% YoY) on EPS of $5.10 (vs $4.75), and TTM EPS of $18.00 is still ~5.9% below the prior TTM of $19.13, so the recovery is real but only one to two quarters old. Free cash flow is wildly seasonal (Q1 FY26 -$1.578B; Q4 FY25 +$2.628B; Q3 FY26 +$1.943B) and should be read annually, not quarterly. Bottom line: revenue has inflected, Q3 margin expanded, and the earnings comparison base for the next two quarters is easy - but with consensus FY2027 EPS flat at $18.13, the inflection is not yet confirmed as an earnings upcycle.

Expensive, and expensive in a way that leaves little room for error. As of 2026-09-13, DE traded at 37.46x TTM EPS of $18.06 against a 5-year average P/E of 17.43x - roughly 2.1x its own history. The forward picture offers no relief: with next-FY consensus EPS of $18.127, the forward P/E is ~37.3x, essentially unchanged, because analysts model flat earnings. Price-to-sales is 3.83 versus a 5-year average of 2.36, and price-to-book is 6.51. PEG is negative (-6.30) and therefore useless as a check. A premium to a farm-machinery peer set is defensible on the mix shift toward precision agriculture and recurring software revenue, but 37x for a company whose TTM EPS is still declining and whose ROIC is 7.1% is a growth multiple applied to a cyclical - it requires either a 2027-2028 earnings recovery well above current consensus or a permanent re-rating of the multiple itself.

The price is doing the work the earnings have not yet done. At $675.74, the market is capitalizing $18.06 of TTM EPS and $18.13 of next-FY consensus EPS at ~37x - so roughly two-thirds of the premium versus the 17.4x five-year average is a bet on the future, not a payment for delivered results. Read it this way: if FY2027 guidance (due with Q4 results on 2026-11-25) lands meaningfully above $19-20 with confirming early-order data, the multiple can hold and the stock can grind toward the $731-$800 targets. If guidance lands near the flat $18 consensus, 37x is unsupported, and a de-rating to a still-generous 25-28x on trough EPS implies $453-$508, while 27x on normalized mid-cycle EPS of ~$21.50 implies ~$580. The asymmetry at this price is modestly negative: you are being paid little for the risk that the 'bottom' call slips a year, and pricing in a recovery before it shows up in estimates is exactly the pattern that punishes cyclical investors.

As of 2026-09-13, RSI(14) stood at 60.83 - bullish momentum, not overbought (below 70), so there is no technical exhaustion signal. Price was 4.42% above its 20-day SMA (~$647), 8.46% above its 50-day SMA (~$623) and 18.10% above its 200-day SMA (~$572), which is a textbook strong uptrend but also an extended one: the last week actually fell -2.57% while the trailing three months gained 17.02%, suggesting the run is taking a breather just under the $705.88 52-week high. Entry-timing implication: chasing a stock 18% above its 200-day after a 17% three-month move is poor risk/reward. The better plan is to let it come to you - a pullback into the $620-$650 zone (50-day/20-day) would offer a far more reasonable entry without breaking the uptrend; a close below the 200-day near $572 would invalidate the bullish technical structure entirely. Beta of 0.911 means this is not a high-volatility mover, so the extension is likely to resolve through time rather than a violent flush.

• Soft global crop prices (corn, wheat, soybeans) plus still-elevated financing costs are compressing farmer purchasing power - large ag shipment volumes were down ~6% YoY in Q3 FY2026 even as revenue rose, meaning price/mix and other segments carried the quarter.
• Tariffs are a direct, quantified drag: roughly $600M-$750M of annual tariff expense, only partially offset by recoveries (a $110M recovery was recorded in Q3 FY2026), alongside ongoing supply-chain re-routing costs.
• Non-ag end markets are a genuine new tailwind - infrastructure funding and AI data-center earthmoving demand drove Construction & Forestry sales up 18% and operating profit up 84%, diversifying DE away from pure farm-cycle exposure.
• Interest rates cut both ways for a captive-finance model: higher funding costs raise Deere Financial's cost of capital and the customer's monthly payment, while the balance sheet carries 2.29x debt-to-equity and a 0.767 current ratio that are structural features of the finance arm, not signs of distress.
• Channel inventory normalization is the key leading macro-adjacent signal: used high-horsepower tractor inventories down ~40% YoY by late summer 2026, which historically precedes a replacement-driven order recovery.
• Sector rotation matters here - DE has re-rated as a 'tech-enabled platform' rather than a machinery cyclical, and that narrative premium is vulnerable if industrial multiples compress.

• Q4 FY2026 earnings on 2026-11-25 (before market open): the first formal FY2027 guidance, FY2027 early-order metrics for high-horsepower equipment, and management commentary on the pace of the farm recovery. This is the single largest swing factor - consensus currently models only $18.13 next-FY EPS, so guidance well above that re-rates the stock and guidance at consensus de-rates it.
• Early order program data for planters and sprayers, which already looks strong enough that Baird upgraded to Outperform with an $800 target on a 'cleanest setup' thesis in North American ag.
• Continued acceleration in Construction & Forestry from infrastructure spending and AI data-center earthmoving - the segment is currently the profit cushion offsetting weak large-ag volumes.
• Precision technology adoption (See & Spray herbicide savings, autonomous tillage) driving mix toward higher-margin, recurring-revenue streams and structurally lifting gross margin over time.
• A recovery in crop prices or a genuine easing in rates, either of which would unlock the deferred farmer replacement cycle faster than consensus assumes.

• Valuation risk is the dominant risk. At 37.46x TTM and ~37.3x forward EPS versus a 17.43x five-year average, DE has no valuation cushion - a single soft guidance quarter can compress the multiple faster than earnings can grow, as illustrated by the $453-$508 implied value at a 25-28x multiple on trough EPS.
• The recovery is priced but not yet in the estimates: next-FY consensus EPS of $18.127 is flat versus $18.06 TTM, so the 'cycle bottom' call is management's and the market's opinion, not the sell-side's numbers. If the ag replacement cycle slips from FY2027 to FY2028, the stock is left holding a growth multiple on flat earnings.
• Macro headwinds on the farmer's balance sheet - low crop prices and high borrowing costs - could keep large-ag volumes depressed for longer than a normal cycle; large ag volumes were still down ~6% YoY in Q3 FY2026.
• Tariff exposure of roughly $600M-$750M annually plus supply-chain friction is a persistent margin leak that management can only partially offset quarter to quarter.
• Financial health optics are genuinely mediocre: debt-to-equity of 2.29, current ratio of 0.767, and a ROIC of only 7.1% - likely below Deere's cost of capital - meaning capital intensity and captive-finance leverage cap the long-run return on incremental investment even in a good year.
• Competitive and cyclical risk in the precision-ag narrative: if the 'tech platform' re-rating unwinds and DE is valued again as a machinery manufacturer, the multiple, not the business, is what breaks.

Deere is a genuinely high-quality franchise and the operational evidence supports management's trough call - revenue has inflected to +7% YoY, Q3 FY2026 operating margin expanded ~230bp, used inventories are down ~40%, and Construction & Forestry is booming. But as of 2026-09-13 at $675.74, the market is paying ~37x TTM and forward EPS that consensus models as flat, versus a 17.4x five-year average - the recovery is being priced before it shows up in estimates, and the stock sits 18% above its 200-day SMA. That is a poor entry point on valuation-adjusted risk/reward: the business is likely at a cyclical bottom, but the stock is not. I would want either a pullback toward the $580-$620 zone or hard FY2027 guidance on 2026-11-25 showing actual earnings growth above the current $18 consensus before treating this as attractive.

I used a cyclical-normalized earnings-power approach: normalizing mid-cycle EPS at $21.50 (a blend of the FY2026 trough of ~$18.00 and FY2024's $25.60 diluted, tilted modestly toward recovery given the 2027 early-order data) and applying a 27x justified P/E - a real premium to the 17.43x five-year average to credit the precision-tech/recurring-revenue mix shift, but well below the current 37x - which yields $580. Cross-checking the other way, 32x on consensus next-FY EPS of $18.127 gives $580.2, so both the normalized and the near-term routes land at the same figure. That is my independent estimate as of 2026-09-13, below both the $675.74 market price and the $731.20 consensus target, and it reflects that the current multiple is capitalizing a recovery that has not yet appeared in consensus estimates.